Skip to content

Study on maternal and infant safety of esketamine in cesarean section under general anesthesia

Study on maternal and infant safety of esketamine in cesarean section under general anesthesia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045020
Enrollment
Unknown
Registered
2021-04-03
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cesarean section under general anesthesia

Interventions

Esketamine:0.25mg/kg Esketamine

Sponsors

Department of Anaesthesiology, the International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 35 Years

Inclusion criteria

Inclusion criteria: Singleton, ASA I-II, age 25-35 years, gestational age 38-40 weeks, body weight 55-75kg, body mass index 20-25kg /m2.

Exclusion criteria

Exclusion criteria: Known allergy to anesthesia inducers, liver and kidney dysfunction, cardiac insufficiency, diabetes mellitus, gestational hypertension, opioid allergy or long-term use of opioids, infection risks such as fever and leukocytosis before operation, perinatal accidents (massive blood loss, etc.), breast development defects, breast feeding contraindications (syphilis, hepatitis, etc.).

Design outcomes

Primary

MeasureTime frame
Heart rate;Blood pressure;Apgar score;VAS score;Oxygen partial pressure;Partial pressure of carbon dioxide;PH value;Umbilical artery and vein blood drug concentration;

Countries

China

Contacts

Public ContactYu-Chien Chao

Department of Anaesthesiology, the International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine

helen750903@163.com+86 13661714818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026